About TransMed7, LLCTransMed7, LLC is a medical and technology based organization focused on the highly efficient development of innovative, minimally invasive medical devices aimed at providing new solutions for doctors and their patients. With particular expertise in both oncologic and cardiovascular disease, TransMed7 and its team of clinicians, scientists, and engineers have developed a portfolio of next-generation platform devices that are expected to be market leaders in their targeted fields of medicine. TransMed7 accomplishes this through application of a wholly new approach in its business plan and structure, enabling these new transformational technologies from rapid development through commercial manufacturing or where appropriate, handoff to our Strategic Partners.
Founder: James W. Vetter and Eugene H. Vetter
Founder and CEO: Eugene H. Vetter
Please click here for TransMed7 job opportunities.
11 articles with TransMed7, LLC
TransMed7, LLC Announces the Availability of Concorde, the Stereotactic Table Variant of its SpeedBird Biopsy Device Platform
“We are delighted to announce a letter-to-file regarding ConcordeTM, the stereotactic table variant of our FDA-cleared SpeedBirdTM soft tissue biopsy device platform,” stated Dr. James W. Vetter, TransMed7 Co-Founder and Chairman.
TransMed7, LLC Announces Appointment of Dr. John Simpson as Strategic Advisor to Its Board of Directors
TransMed7, LLC is delighted to announce the appointment of John B. Simpson, Ph.D., M.D., as Strategic Advisor to the TransMed7 Board of Directors.
TransMed7, LLC Announces 510(k) Clearance by the U.S. FDA for its SpeedBird Soft Tissue Biopsy Device Platform
The SpeedBird platform is based on TransMed7’s patented Zero5TM work element composed of a fused, single element constructed from 3 hypotubes and forming rotating twin cutter blades.
Mr. David Harding is currently the Senior Vice-President (SVP) of Corporate Strategy and Business Development at Exact Sciences, a diagnostics company focused on colorectal cancer screening.
The TransMed7 BAB is composed of accomplished business experts offering innovative advice and dynamic perspectives that will contribute to the accomplishment of TransMed7’s tactical goals and strategic objectives.
Transmed7 Announces 510(K) Submission to the FDA for Its Speedbird Soft Tissue Biopsy Device Platform
The company has submitted a premarket notification for its innovative SpeedBird soft tissue biopsy device platform with FDA.